Press offices

Press offices

SMC Spain amplifies the voices of experts on controversial current affairs.

¿Qué me ofrece?

Sources who collaborate with us will multiply their national and international media impact. Register your office to be part of a directory on this website that journalists will be able to consult. Our guides on communication and science can help you in your daily work.

Icono
Cómo trabajamos

When we contact a source that is part of your institution, we will inform you. We will contact you when we organise briefings with scientists from your organisation. We will provide with support resources to facilitate your work. You can find out more about how we work here.   

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

Reaction: mice that confront the aggressor develop greater resilience than those that flee

A study in mice published in the journal Nature has analysed the different responses to aggression and the consequences for subsequent behaviour. In general, animals that confronted the aggressor developed greater resilience than those that fled or avoided the aggressor, and the gain was greater as brain circuits associated with dopamine were activated.

0

Reaction to study claiming that life expectancy recovered in 2021 in some countries, including Spain

Research published in Nature Human Behaviour analyses changes in life expectancy since the advent of covid-19. Its findings show that some countries in western Europe, including Spain, regained some of their lost life expectancy, and others returned to 2019 levels. On the other hand, losses continued in Eastern Europe and the United States.

0

Reactions: EMA gives green light to new dengue vaccine

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for the tetravalent dengue vaccine (live, attenuated) Takeda. The vaccine is intended to prevent disease caused by dengue virus serotypes 1, 2, 3 and 4 in people aged four years and older. Although an approved vaccine already exists, according to the EMA, this quadrivalent vaccine shows increased protection in children and people over 45 years of age.

0